Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 8/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.36 |
| ▸ | ADRA2B | P18089 | 4/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 4/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.36 |
| ▸ | MTHFD2 | P13995 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 3/20 | 0.35 |
| ▸ | DRD4 | P21917 | 3/20 | 0.35 |
| ▸ | DRD3 | P35462 | 2/20 | 0.35 |
| ▸ | F10 | P00742 | 1/20 | 0.33 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.33 |
| ▸ | FNTA | P49354 | 1/20 | 0.33 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15769296 | 0.95 | MCHR1 (0.40) | MCHR1ADRA2AADRA2BADRA2CADRA1A | |
| SCHEMBL15768941 | 0.91 | MCHR1 (0.41) | MCHR1MTHFD2 | |
| SCHEMBL15769267 | 0.89 | MCHR1 (0.39) | MCHR1ADRA2AADRA2BADRA2CADRA1A | |
| SCHEMBL15769194 | 0.88 | MCHR1 (0.52) | MCHR1ADRA2AADRA2BADRA2CADRA1A | |
| SCHEMBL15781261 | 0.86 | MCHR1 (0.44) | MCHR1DRD2DRD4DRD3FNTA | |
| SCHEMBL15769715 | 0.86 | MCHR1 (0.43) | MCHR1MTHFD2 | |
| SCHEMBL15769478 | 0.85 | MCHR1 (0.46) | MCHR1ADRA2AADRA2BADRA2CADRA1A | |
| Hydrochloric Acid SCHEMBL15768910 | 0.85 | MCHR1 (0.46) | MCHR1ADRA2AADRA2BADRA2CADRA1A | |
| SCHEMBL15769539 | 0.85 | MCHR1 (0.38) | MCHR1ADRA2AADRA2BADRA2CADRA1A | |
| SCHEMBL15781379 | 0.85 | MCHR1 (0.53) | MCHR1DRD2DRD4DRD3FNTA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140163012-A1 | PYRIDO-/AZEPINO-BENZOFURAN AND PYRIDO-/AZEPINO-BENZOTHIOPHENE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USE THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2014-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140163012-A1 | PYRIDO-/AZEPINO-BENZOFURAN AND PYRIDO-/AZEPINO-BENZOTHIOPHENE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USE THEREOF | MCHR1, MCHR2, TAAR1 | MCHR1 1/4885ADRA2A 754/4885ADRA2B 504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.